Table 2 Sputum-smear and culture conversion time in per protocol group i.e. patients who completed the treatment.

From: Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial

Week

Smear conversion till (in weeks)

P

Odds Ratio (95% C.I.)

Culture conversion till (in weeks)

P

Odds Ratio (95% C.I.)

MIP Arm (N = 328)

Placebo Arm(N = 314)

MIP Arm (N = 328)

Placebo Arm (N = 314)

Converted (Cumulative numbers)

%

Converted (Cumulative numbers)

%

Converted (Cumulative numbers)

%

Converted (Cumulative numbers)

%

2

175

53.35

153

48.7

0.24

1.2 (0.87–1.66)

139

42.37

118

37.5

0.215

1.22 (0.87–1.69)

4

234

71.34

216

68.78

0.48

1.13 (0.79–1.61)

220

67.1

179

57.0

0.0002*

1.86 (1.31–2.64)

6

268

81.7

242

77.1

0.146

1.33 (0.89–1.98)

257

78.35

215

68.47

0.0046*

1.67 (1.15–2.41)

8

281

85.67

261

83.1

0.37

1.21 (0.77–1.9)

286

87.1

248

78.98

0.0054*

1.8 (1.16–2.84)

12

298

90.85

274

87.3

0.14

1.45 (0.85–2.48)

301

91.77

269

85.67

0.014*

1.86 (1.1–3.22)

16

303

92.37

280

89.17

0.16

1.47 (0.82–2.64)

303

92.37

270

85.98

0.009*

1.97 (1.14–3.46)

26

305

92.98

283

90.13

0.19

1.45 (0.79–2.67)

306

93.29

275

87.58

0.0136*

1.97 (1.1–3.58)

35

306

93.29

283

90.13

0.15

1.52 (0.83–2.83)

306

93.29

277

88.2

0.026**

1.86 (1.03–3.39)

36

  

309

94.2

280

89.17

0.02*

1.97 (1.06–3.75)

39

309

94.2

284

90.4

0.073

1.72 (0.91–3.3)

309

94.2

280

89.17

0.02*

1.97 (1.06–3.75)

40

  

 

281

89.49

  

Median Time (range)

2 (2–39)

2 (2–39)

  

4 (2–36)

4 (2–40)

  
  1. *P value significant after Boneferroni’s correction. **Corrected p value not significant.